Crescent Biopharma filings document a clinical-stage oncology biotechnology issuer with ordinary shares listed on Nasdaq. The company’s Form 8-K reports furnish quarterly and annual financial results, business highlights, and pipeline updates involving CR-001, ADC programs, and collaboration activity.
Its SEC record also includes a definitive proxy statement covering governance, executive compensation, equity awards, shareholder voting matters, and board-related disclosures. Registration statement materials describe the company’s business, capitalization, preferred stock, warrants, convertible instruments, risk factors, and public-company structure.
CRESCENT BIOPHARMA, INC. (CBIO) reported that President and COO Jonathan McNeill sold a total of 4,570 Ordinary Shares in open market transactions on September 16 and 18, 2026. The sales were made under a Rule 10b5-1 trading instruction adopted on February 25, 2026 and were executed solely to cover tax withholding obligations tied to vesting restricted stock units.
Crescent Biopharma, Inc. (CBIO) is the issuer for a Rule 144 notice filed for the account of Joshua T. Brumm covering proposed sales of its ordinary shares.
The notice reports a planned sale of 16,775 ordinary shares, acquired through restricted stock unit vesting from the issuer on September 17, 2026 as compensation for services. It also lists sales during the past three months of 42,305 ordinary shares on June 22, 2026 for $761,257.32 and 1,610 ordinary shares on September 16, 2026 for $28,815.62. Securities information shows 9,013 ordinary shares in a Morgan Stanley Smith Barney LLC Executive Financial Services account, with an associated value of $154,843.34 and a date of September 18, 2026.
Crescent Biopharma, Inc. officer Jonathan McNeill reported plans to sell 4,415 ordinary shares, with an approximate sale date of September 18, 2026 and an aggregate market value of $75,849.70. The reported Rule 10b5-1 plan-adoption or instruction date is February 25, 2026.
McNeill acquired 8,387 ordinary shares through restricted stock unit vesting on September 17, 2026, for services rendered. Sales reported during the past three months included 20,549 shares for gross proceeds of $369,768.98 on June 22, 2026, and 731 shares for gross proceeds of $13,083.36 on September 16, 2026.
CRESCENT BIOPHARMA, INC. (CBIO) is the issuer for a planned resale of its ordinary shares under Rule 144 by Jonathan McNeill. The notice lists a proposed sale of 804 ordinary shares, with an aggregate market value of $15,115.20, on or after September 16, 2026, on Nasdaq. McNeill previously acquired 1,595 shares through restricted stock unit vesting on September 15, 2026 and sold 20,549 shares for $369,768.98 on June 22, 2026.
CRESCENT BIOPHARMA, INC. (CBIO) is the issuer for which a Form 144 notice has been filed relating to planned sales of its ordinary shares by Joshua T. Brumm. The notice lists 1,771 ordinary shares to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $33,294.80 as of September 16, 2026, on Nasdaq.
The filing also notes 3,444 ordinary shares underlying restricted stock units scheduled to vest on September 15, 2026, as compensation for services rendered by the issuer, and discloses that 42,305 ordinary shares were sold during the prior three months on June 22, 2026 for $761,257.32. The notice is signed on behalf of Brumm by Barbara Bispham Hale as Attorney-in-Fact.
Balyasny Asset Management L.P. and affiliated entities report beneficial ownership of Crescent Biopharma, Inc. common stock. Through Atlas Private Holdings (Cayman) Ltd., which directly holds 670,000 Shares, and Atlas Diversified Master Fund, Ltd., which directly holds 992,917 Shares, the group may be deemed to beneficially own a total of 1,662,917 Shares of Class A common stock.
These Shares represent approximately 6.03% of Crescent Biopharma’s Class A common stock, based on 27,571,935 Shares outstanding as of April 24, 2026. Each reporting person—Balyasny Asset Management L.P., BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny—is listed with sole voting and dispositive power over 1,662,917 Shares and no shared power. ADMF and APHC have the right to receive dividends and sale proceeds from these securities.
Crescent Biopharma, Inc. is filing Post-Effective Amendment No. 2 to convert an existing Form S-1 into a Form S-3 shelf registration for the resale of up to 18,154,836 Ordinary Shares by existing investors. These Resale Shares include Ordinary Shares issued in a December 8, 2025 private placement, shares issuable upon exercise of pre-funded warrants, and shares issuable upon conversion of Series A non-voting convertible preferred shares held by Fairmount Healthcare Fund II L.P. As of July 22, 2026, at least 1,555,421 previously registered private placement shares have already been sold and are excluded from this prospectus.
The company is not selling any shares in this offering and will not receive proceeds from Selling Securityholders’ resales, other than the nominal cash exercise price if pre-funded warrants are exercised, which it intends to use for general corporate purposes. Ordinary shares were 37,143,940 outstanding as of July 22, 2026, and trade on Nasdaq Capital Market under the symbol CBIO, with a last reported price of $14.77 per share on July 29, 2026.
Crescent Biopharma, Inc. is registering for resale by selling securityholders up to 19,580,843 ordinary shares, including outstanding shares and shares issuable from pre-funded warrants and conversion of 2,890 Series A non-voting convertible preferred shares. The company’s ordinary shares trade on Nasdaq under “CBIO”; the closing price was $14.77 on July 29, 2026.
As of June 30, 2026, Crescent reported $171.6 million in cash and cash equivalents and total assets of $182.8 million, with total liabilities of $19.5 million and shareholders’ equity of $163.3 million. The company generated $1.0 million of license revenue in the first half of 2026 and recorded a net loss of $48.1 million, driven by $37.3 million in research and development and $16.6 million in general and administrative expenses.
Crescent is a clinical-stage oncology company developing programs such as CR-001 and CR-002 under license from Paragon Therapeutics, and SKB105 (CR-003) under license from Kelun. It reported net cash used in operating activities of $28.4 million for the six months ended June 30, 2026 and expects existing cash, together with proceeds from a July 2026 underwritten offering, to fund operations for at least twelve months from issuance of these financial statements.
Crescent Biopharma, Inc., a clinical-stage oncology company, reported a net loss of $24.8 million for Q2 2026 and $48.1 million for the first half of 2026. License revenue totaled $1.0 million year-to-date from its CR-001 collaboration with Kelun, with no revenue in the second quarter.
Operating expenses increased as the pipeline advanced: research and development was $19.4 million in Q2 and $37.3 million year-to-date, while general and administrative costs were $8.7 million in Q2 and $16.6 million year-to-date. Interest expense from prior convertible notes was eliminated after their 2025 conversion, and Crescent booked $1.8 million of other income from a gain on sale of assets.
Cash and cash equivalents were $171.6 million as of June 30, 2026, down from $213.2 million at year-end, after $28.4 million of operating cash outflows and $6.4 million used in investing, including an $80.0 million SKB105 (CR-003) license from Kelun. Total liabilities were modest at $19.5 million against $163.3 million of shareholders’ equity. Management expects existing cash, together with an underwritten offering completed in July 2026, to fund operations for at least twelve months from issuance.